RU2131737C1 - Agent "espokrasil" for treatment and prophylaxis of ischemic heart disease and dislipoproteidemia - Google Patents

Abstract

FIELD: medicine, phytotherapy. SUBSTANCE: agent - 40% alcohol tincture prepared of the following plants, wt.-%: blood-red haw-thorn or other species 40; tatarica or drooping catchfly herb 20; blue Greek valerian rhizomes and roots 20 and horse chestnut seeds 20. Agent can be used for treatment and prophylaxis of ischemic heart disease and lipoproteidemia both separately and in the complex with other similar agents. EFFECT: simplified method of preparing, absence of adverse responses, decreased cost. 3 ex

Description

 The invention relates to medicine, namely to phytotherapeutic agents for the treatment and prevention of coronary heart disease (CHD), complicated by dyslipoproteinemia, taken alone, and also in combination with coronary expansion, antispasmodic, anti-inflammatory, non-specific immunocorrection therapy and physiotherapy.

 The tool has anti-sclerotic, analgesic, antiarrhythmic, sedative effects.

 At present, the relationship between dyslipoproteinemia and the development of ischemic heart disease has been proven. It seems extremely important to find ways and means for the prevention and treatment of patients with coronary artery disease and atherosclerosis.

 It is known to use herbal remedies used for a similar purpose, for example, cardiotonic glycosides, alkaloids quinidine, aymalin, individual plants - hawthorn, valerian, etc., as well as complex preparations (pulsnorm, lipostabil, lipomal, etc. (1, 2)). However, many of these drugs are imported, their production is complex and expensive. In addition, many of them are quite toxic, for example, quinidine, aymalin, pulsnorm with a limited range of their therapeutic effects. Taking drugs for the treatment of dyslipoproteinemia such as lipostabil, lipomal is associated with the possibility of complications: diarrhea, vomiting, flatulence, epigastric pain, etc.

 The search and production of this kind of drugs is an extremely important task, which can be solved by preparing drugs on the basis of fees compiled taking into account many therapeutic and technological factors (3). Such phytocompositions are able to be developed by people with special pharmaceutical and medical education, high qualifications and extensive experience working with medicinal plants.

 The basis of the invention is the goal of creating such a drug for the treatment of patients with coronary heart disease with impaired lipoprotein and cholesterol metabolism, which would be highly effective, had no undesirable side effects, was simple to manufacture, contained affordable and inexpensive components.

The problem is solved in that the tool is made on the basis of a collection having the following composition, in parts:
Fruits of hawthorn blood red and other species - 2
Grass of tar of Tatar or drooping - 1
Rhizomes with blue cyanosis roots - 1
Horse chestnut seed - 1
The tool is invited to assign the name "Espokrasil."

 The components of the collection are not potent, do not have contraindications in therapeutic doses, are available. Raw materials from plants were collected at the optimum time; primary processing, drying, bringing to standard condition was carried out in accordance with the requirements of the State Pharmacopoeia (4).

 Considering that the expected therapeutic effect is determined mainly by phytoecdysteroids, flavonoids, phenolcarboxylic acids, saponins, the collection was carried out with 40% alcohol as follows: 50 g of the collection was filled with 100 ml of 40% alcohol, insisted for 3 days, after which the raw material was squeezed , added to it 100 ml of 40% alcohol and insisted 1 day. The raw materials were squeezed and a third time was poured into 100 ml of 40% alcohol. Insisted for 1 day and squeezed. After combining all the extracts, 250 ml of tincture was obtained, which was filtered.

 The tincture is a clear liquid, reddish-brown in color, bitter taste, a slight peculiar smell. Patients took 30 drops 3 times a day before meals for one month.

 We studied the effect of Espokrasil on the dynamics of the lipid spectrum in patients with coronary artery disease and dyslipoproteinemia. The study included 46 patients with coronary artery disease, including 36 men and 10 women. Of these, 33 patients suffered from progressive angina pectoris (with an outcome in FC-II angina pectoris - 21 patients; with an outcome in FC-III-13 patients), and 13 patients had angina pectoris (FC-II - 5 patients; FC-III - 8 sick). The age of patients is from 29 to 69 years. Plasma concentrations of total cholesterol, triglycerides, α-cholesterol, β-lipoproteins, atherogenicity coefficient, blood enzyme spectrum, prothrombin index, total bilirubin, creatinine, hematological analyzes, electrocardiography in dynamics, heart ultrasound were studied. Exclusion criteria from the study were: age older than 70 years, the presence of hypothyroidism, diabetes mellitus, nephrotic syndrome, liver damage, FC-IV angina pectoris, heart failure stage II and III. On the recommendation of the WHO, hypercholesterolemia was considered at a cholesterol level of more than 6.72 mmol / l; hypertriglyceridemia - more than 2.26 mmol / l; hypo-α- cholesterolemia - less than 0.088 mmol / l.

 The hypolipidemic effect of “Espokrasil” was manifested in 40 patients (86.9%), especially clearly in 10 patients, where the atherogenicity coefficient decreased by almost 3 times, which significantly improved the prognosis of such patients when dietary recommendations were observed: a reduced content of saturated fat and cholesterol.

 The invention is illustrated by the following examples.

 Example 1. B. K., 52 years old. Diagnosis: CHD: angina pectoris FC-II.

Before treatment with Espokrasil - After treatment
Cholesterol 4.06 mmol / L - 5.41 mmol / L
α-cholesterol 0.68 mmol / L - 1.69 mmol / L
Triglycerides 1.31 mmol / L - 1.69 mmol / L
β-lipoproteins 28 units - 33 units.

Coeff. atherogenicity 4.97 - 2.2
Example 2. B-th M., 51 years old. Diagnosis: coronary heart disease: angina pectoris FC-III. Hypertension of the II stage, obesity of the III degree, weight 112 kg.

Before treatment with Expocrasil - After treatment
Cholesterol 8.11 mmol / L - 6.08 mmol / L
α-cholesterol 0.85 mmol / L - 1.36 mmol / L
Triglycerides 6.4 mmol / L - 1.41 mmol / L
β-lipoproteins 130 units. - 38 units

Coeff. atherogenicity 8.54 - 3.5
Example 3. B-naya J., 53 goals. Diagnosis: CHD: angina pectoris FC-III, atrial extrasystole.

Before treatment with Espokrasil - After treatment
Cholesterol 5.75 mmol / L - 4.73 mmol / L
α-cholesterol 0.85 mmol / L - 1.02 mmol / L
Triglycerides 6.6 mmol / L - 3.04 mmol / L
Coeff. atherogenicity 5.76 - 3.63
After treatment with "Espokrasil" - the correct sinus rhythm.

 Thus, the ability of Espokrasil is noted not only to normalize the ratio of atherogenic and antiatherogenic lipoproteins in blood plasma, but also to slow down the process of their modifications. "Espokrasil" is an effective and safe tool that provides a pronounced hyposolesterolemic effect, a decrease in triglycerides and an atherogenic index. This is especially pronounced in the group of patients with various manifestations of coronary heart disease and concomitant obesity.

 Sources of information.

 1. Mashkovsky M. D. Medicines, ed. 10, part I, M., Medicine, 1987, p. 401 - 409.

 2. Medicines of foreign companies in Russia. M., "Astrafarmservis", 1993, p. 360.

 3. Petkov V. et al. Modern herbal medicine. Sofia, "Medicine and Physical Education", 1988.

 4. State Pharmacopoeia, ed. II, c. 2, M., Medicine, 1990.

Claims (1)

A tool for the treatment and prevention of coronary heart disease and dyslipoproteinemia based on 40% water-alcohol tincture of the fruits of hawthorn blood-red or other species, characterized in that it additionally contains grass of Tatar or drooping tar, rhizome with blue cyanosis roots and chestnut seeds horse at a ratio of components, wt.%:
Fruits of hawthorn blood red or other species - 40.0
Grass of tar of Tatar or drooping - 20.0
Rhizome with blue cyanosis roots - 20.0
Horse chestnut seeds - 20.0